Last updated: 15:56
No Notes Added Yet
Sunrest Lifescience Ltd. is an Indian pharmaceutical and healthcare company that was originally incorporated as a private limited company in October 2017 and later converted into a public limited company in March 2023. It is engaged primarily in the marketing and distribution of over‑the‑counter (OTC) generic pharmaceutical products across several Indian states including Maharashtra, Gujarat, Madhya Pradesh, Odisha and Rajasthan. The company’s product portfolio spans a wide range of forms such as capsules, tablets, syrups, ointments, gels...Read More
Sunrest Lifescience Ltd. is an Indian pharmaceutical and healthcare company that was originally incorporated as a private limited company in October 2017 and later converted into a public limited company in March 2023. It is engaged primarily in the marketing and distribution of over‑the‑counter (OTC) generic pharmaceutical products across several Indian states including Maharashtra, Gujarat, Madhya Pradesh, Odisha and Rajasthan. The company’s product portfolio spans a wide range of forms such as capsules, tablets, syrups, ointments, gels, mouthwash, solutions, suspensions, dry powders and toothpaste, covering therapeutic categories like anti‑bacterials, anti‑diarrheal, anti‑fungal, anti‑diabetic, anti‑hypertensive, nutraceuticals and cosmetic products. Sunrest outsources manufacturing to third‑party manufacturers, including a group company, and has built a network of registered trademarks for multiple products. It raised capital through an SME public issue in 2023 to support expansion and working capital requirements and has also acquired a majority stake in Hetvi Lifesciences Private Limited as a subsidiary, reflecting its efforts to grow within the domestic pharmaceutical market. ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹31 Cr.
Stock P/E 15.4
P/B 1.5
Current Price ₹36.1
Book Value ₹ 24
Face Value 10
52W High ₹54.4
Dividend Yield 0%
52W Low ₹ 26.4
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) |
|---|
| Net Sales |
| Other Income |
| Total Income |
| Total Expenditure |
| Operating Profit |
| Interest |
| Depreciation |
| Exceptional Income / Expenses |
| Profit Before Tax |
| Provision for Tax |
| Profit After Tax |
| Adjustments |
| Profit After Adjustments |
| Adjusted Earnings Per Share |
| #(Fig in Cr.) | Mar 2025 | TTM |
|---|---|---|
| Net Sales | 33 | |
| Other Income | 0 | |
| Total Income | 33 | |
| Total Expenditure | 30 | |
| Operating Profit | 3 | |
| Interest | 0 | |
| Depreciation | 0 | |
| Exceptional Income / Expenses | 0 | |
| Profit Before Tax | 3 | |
| Provision for Tax | 1 | |
| Profit After Tax | 2 | |
| Adjustments | -0 | |
| Profit After Adjustments | 2 | |
| Adjusted Earnings Per Share | 4.7 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 0% | 0% | 0% | 0% |
| Operating Profit CAGR | 0% | 0% | 0% | 0% |
| PAT CAGR | 0% | 0% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -26% | NA% | NA% | NA% |
| ROE Average | 12% | 12% | 12% | 12% |
| ROCE Average | 10% | 10% | 10% | 10% |
| #(Fig in Cr.) | Mar 2025 |
|---|---|
| Shareholder's Funds | 16 |
| Minority's Interest | 5 |
| Borrowings | 6 |
| Other Non-Current Liabilities | -0 |
| Total Current Liabilities | 31 |
| Total Liabilities | 58 |
| Fixed Assets | 4 |
| Other Non-Current Assets | 0 |
| Total Current Assets | 54 |
| Total Assets | 58 |
| #(Fig in Cr.) | Mar 2025 |
|---|---|
| Opening Cash & Cash Equivalents | 0 |
| Cash Flow from Operating Activities | 3 |
| Cash Flow from Investing Activities | -1 |
| Cash Flow from Financing Activities | -0 |
| Net Cash Inflow / Outflow | 1 |
| Closing Cash & Cash Equivalent | 2 |
| # | Mar 2025 |
|---|---|
| Earnings Per Share (Rs) | 4.67 |
| CEPS(Rs) | 4.91 |
| DPS(Rs) | 0 |
| Book NAV/Share(Rs) | 38.01 |
| Core EBITDA Margin(%) | 9.04 |
| EBIT Margin(%) | 8.77 |
| Pre Tax Margin(%) | 7.85 |
| PAT Margin (%) | 6.02 |
| Cash Profit Margin (%) | 6.3 |
| ROA(%) | 3.45 |
| ROE(%) | 12.33 |
| ROCE(%) | 10.33 |
| Receivable days | 397.25 |
| Inventory Days | 105.13 |
| Payable days | 417.13 |
| PER(x) | 11.5 |
| Price/Book(x) | 1.26 |
| Dividend Yield(%) | 0 |
| EV/Net Sales(x) | 1 |
| EV/Core EBITDA(x) | 11.04 |
| Net Sales Growth(%) | 0 |
| EBIT Growth(%) | 0 |
| PAT Growth(%) | 0 |
| EPS Growth(%) | 0 |
| Debt/Equity(x) | 0.74 |
| Current Ratio(x) | 1.73 |
| Quick Ratio(x) | 1.42 |
| Interest Cover(x) | 9.58 |
| Total Debt/Mcap(x) | 0.52 |
| # | Mar 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoter | 69.91 | 69.91 | 69.91 | 69.91 | 69.91 | 53.5 | 53.5 | 53.5 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 30.09 | 30.09 | 30.09 | 30.09 | 30.09 | 46.5 | 46.5 | 46.5 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoter | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.23 | 0.23 | 0.23 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.13 | 0.13 | 0.13 | 0.13 | 0.13 | 0.2 | 0.2 | 0.2 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 0.43 | 0.43 | 0.43 | 0.43 | 0.43 | 0.43 | 0.43 | 0.43 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
ChatGPT
Claude
Perplexity
